Previous 10 | Next 10 |
2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...
2024-05-31 12:09:24 ET More on Calliditas Therapeutics Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Call Transcript Calliditas Therapeutics AB (publ) 2024 Q1 - Results - Earnings Call Presentati...
2024-05-30 21:15:02 ET Citigroup analyst issues NEUTRAL recommendation for CALT on May 30, 2024 07:46PM ET. CALT was trading at $38.4716 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 3 - Hold recommend...
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy PR Newswire STOCKHOLM , May 30, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...
2024-05-29 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 46.0% to $0.2601 on volume of 655,453,952 shares Sharps Technology Inc. (STSS) rose 141.4% to $0.5174 on volume of 299,690,189 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.4% to $0.0786 on...
2024-05-28 16:00:06 ET Maury Raycroft from Jefferies issued a price target of $39.00 for CALT on 2024-05-28 13:15:00. The adjusted price target was set to $39.00. At the time of the announcement, CALT was trading at $37.955. The overall price target consensus is at $49.0...
2024-05-28 15:30:03 ET Jefferies analyst issues HOLD recommendation for CALT on May 28, 2024 01:23PM ET. The previous analyst recommendation was Buy. CALT was trading at $37.95 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current anal...
2024-05-28 14:04:21 ET More on Mid-day movers & stock Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage Semler Scientific, Inc. (SMLR) Q1 2024 Earnings Call Transcript G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript A...
2024-05-28 13:35:36 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...